Dr. Song's experience spans clinical medicine, basic science research, venture capital, and entrepreneurship. As co-inventor of Ariosa's flagship product he successfully led the organization from early research to product development to commercialization in over 100 countries. Prior to Ariosa, Dr. Song was a venture capital investor at Venrock and served as a consultant at McKinsey & Company. Dr. Song trained in internal medicine at the University of California, San Francisco (UCSF) and then went on to specialize in gastroenterology and hepatology at the University of Washington along with a scientific fellowship at the Fred Hutchinson Cancer Center. He received his B.S. in Biology from the Massachusetts Institute of Technology, and his M.D. from the University of California, San Francisco.
"I'm thrilled to have the opportunity to lead Metacrine and work with an outstanding team and group of investors," said Dr. Song. "With the company's two mechanistically distinct programs targeting large clinical needs, I believe Metacrine has the potential to bring forth novel medicines that can positively impact tens of millions of people."
Metacrine is a privately-held biotechnology company headquartered in San Diego, CA. The company is focused on advancing research in nuclear hormone receptors for treatment of metabolic diseases. For more information, visit www.metacrine.com.
Logo - http://photos.prnewswire.com/prnh/20160912/406819LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/metacrine-announces-appointment-of-dr-ken-song-as-president-and-chief-executive-officer-300327087.html